Rift Valley fever vaccines

an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination. This vaccine strain is well attenuated, and a single dose induces neutralizing antibodies in both ruminants and humans. Areas covered: This review describes scientific evidences of MP-12 vaccine efficacy and safety, as well as MP-12 variants recently developed by reverse genetics, in comparison with other RVF vaccines. Expert commentary: The containment of active RVF outbreaks and long-term protection from RVF exposure to infected mosquitoes are important goals for RVF vaccination. MP-12 vaccine will allow immediate vaccination of susceptible animals in case of an unexpected RVF outbreak in the U.S., whereas MP-12 vaccine may be also useful for the RVF control in endemic regions.

Original languageEnglish (US)
Pages (from-to)601-611
Number of pages11
JournalExpert Review of Vaccines
Volume16
Issue number6
DOIs
StatePublished - Jun 3 2017

Fingerprint

Rift Valley Fever
Vaccines
Safety
Rift Valley fever virus
Disease Outbreaks
Vaccination
Ruminants
Culicidae
Reverse Genetics
Induced Abortion
Zoonoses
Virus Diseases
Neutralizing Antibodies
Fever
Public Health

Keywords

  • efficacy
  • MP-12 vaccine
  • reverse genetics
  • Rift Valley fever
  • safety

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Rift Valley fever vaccines : an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. / Ikegami, Tetsuro.

In: Expert Review of Vaccines, Vol. 16, No. 6, 03.06.2017, p. 601-611.

Research output: Contribution to journalReview article

@article{673d3b0106d64d318bb24e5dfcea0b2c,
title = "Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate",
abstract = "Introduction: Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination. This vaccine strain is well attenuated, and a single dose induces neutralizing antibodies in both ruminants and humans. Areas covered: This review describes scientific evidences of MP-12 vaccine efficacy and safety, as well as MP-12 variants recently developed by reverse genetics, in comparison with other RVF vaccines. Expert commentary: The containment of active RVF outbreaks and long-term protection from RVF exposure to infected mosquitoes are important goals for RVF vaccination. MP-12 vaccine will allow immediate vaccination of susceptible animals in case of an unexpected RVF outbreak in the U.S., whereas MP-12 vaccine may be also useful for the RVF control in endemic regions.",
keywords = "efficacy, MP-12 vaccine, reverse genetics, Rift Valley fever, safety",
author = "Tetsuro Ikegami",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/14760584.2017.1321482",
language = "English (US)",
volume = "16",
pages = "601--611",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Rift Valley fever vaccines

T2 - an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate

AU - Ikegami, Tetsuro

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Introduction: Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination. This vaccine strain is well attenuated, and a single dose induces neutralizing antibodies in both ruminants and humans. Areas covered: This review describes scientific evidences of MP-12 vaccine efficacy and safety, as well as MP-12 variants recently developed by reverse genetics, in comparison with other RVF vaccines. Expert commentary: The containment of active RVF outbreaks and long-term protection from RVF exposure to infected mosquitoes are important goals for RVF vaccination. MP-12 vaccine will allow immediate vaccination of susceptible animals in case of an unexpected RVF outbreak in the U.S., whereas MP-12 vaccine may be also useful for the RVF control in endemic regions.

AB - Introduction: Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination. This vaccine strain is well attenuated, and a single dose induces neutralizing antibodies in both ruminants and humans. Areas covered: This review describes scientific evidences of MP-12 vaccine efficacy and safety, as well as MP-12 variants recently developed by reverse genetics, in comparison with other RVF vaccines. Expert commentary: The containment of active RVF outbreaks and long-term protection from RVF exposure to infected mosquitoes are important goals for RVF vaccination. MP-12 vaccine will allow immediate vaccination of susceptible animals in case of an unexpected RVF outbreak in the U.S., whereas MP-12 vaccine may be also useful for the RVF control in endemic regions.

KW - efficacy

KW - MP-12 vaccine

KW - reverse genetics

KW - Rift Valley fever

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85019254266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019254266&partnerID=8YFLogxK

U2 - 10.1080/14760584.2017.1321482

DO - 10.1080/14760584.2017.1321482

M3 - Review article

VL - 16

SP - 601

EP - 611

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -